News Room

News Releases

Sep. 19, 2018 (PDF/79KB)CSR

Sumitomo Dainippon Pharma Contributes to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan
Sep. 10, 2018 (PDF/210KB)R&D

Results of Phase 3 Studies Evaluating Patch Formulation of Atypical Antipsychotic LONASEN Presented at Congress
Sep. 03, 2018 (PDF/129KB)Corporate

Sumitomo Dainippon Pharma announces personnel changes
Sep. 01, 2018 (PDF/228KB)R&D

FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
Jul. 31, 2018 (PDF/107KB)R&D

New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
Jul. 30, 2018 (PDF/84KB)R&D

Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin Physician-initiated Clinical Trials for Parkinson's Disease that Transplants Dopamine progenitor cells generated from Induced Pluripotent Stem (iPS) Cells
Jul. 27, 2018 (PDF/468KB)Finances

Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2019
Jul. 27, 2018 (PDF/197KB)Finances

Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2019 [IFRS]
Jul. 26, 2018 (PDF/323KB)R&D

Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
Jul. 23, 2018 (PDF/103KB)CSR

Sumitomo Dainippon Pharma Contributes to The Heavy Rain Event of July 2018 in Japan

Dec. 02, 2013 (PDF/414KB)R&D

Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)